UnitedHealthcare Sacral Nerve Stimulation Coverage Update

Coverage Criteria — Sacral Nerve Stimulation

Screening Trial — Urinary

Covered when ALL of the following are met

Urinary SNS screening trial: Lower urinary tract symptoms (one or more: overactive bladder/urgency-frequency syndrome, urge urinary incontinence, nonobstructive urinary retention)

Bladder capacity of 100 mL or greater>=100 mL

Non-neurologic origin: Urinary dysfunction is not secondary to a neurologic disease (e.g., Parkinson's disease, stroke, spinal cord injury, multiple sclerosis)

No mechanical obstruction: No bladder outlet or mechanical obstruction (e.g., benign prostatic hyperplasia, tumor or prior radiation causing obstruction, urethral stricture)

Refractory to conservative care: Symptoms refractory to conservative care (e.g., bladder training, pelvic floor rehabilitation, pharmacologic therapy)

Ability to operate device: Individual capable of operating sacral nerve stimulating device

Permanent Implantation — Urinary

Covered when ALL of the following are met

Prior trial criteria: All criteria for Sacral Nerve Stimulation screening trial have been met

Responder: Improvement in reported symptoms of 50% or greater in response to a screening trial of Sacral Nerve Stimulation>=50%

Screening Trial — Fecal Incontinence

Covered when ALL of the following are met

Refractory to conservative care (FI): Symptoms refractory to conservative care (e.g., bowel training, bulking agents, pelvic floor rehabilitation, pharmacologic therapy)

Ability to operate device: Individual capable of operating sacral nerve stimulating device

Non-neurologic origin (FI): Fecal incontinence is not secondary to a neurologic disease (e.g., Parkinson's disease, stroke, spinal cord injury, multiple sclerosis)

Not secondary to constipation: Fecal incontinence is not secondary to constipation

Permanent Implantation — Fecal Incontinence

Covered when ALL of the following are met

Prior trial criteria (FI): All criteria for Sacral Nerve Stimulation screening trial for fecal incontinence have been met

Responder (FI): Improvement in reported symptoms of 50% or greater in response to a screening trial of Sacral Nerve Stimulation>=50%

Device Replacement/Revision

Replacement/Revision: Replacement or revision of a sacral nerve stimulator is medically necessary when the individual met all selection criteria and the existing device is nonfunctional and cannot be repaired or is no longer under warranty

Trial-defined criteria and evidence summaries relevant to coverage decisions

Coverage-relevant clinical scenarios and typical trial-defined criteria

Test stimulation and prior therapy: Candidate has failed behavioral and pharmacologic therapy AND undergoes an initial test stimulation phase with documented response>=50% improvement or <8 voids/day

Multiple systematic reviews and trials use this sequence and threshold for proceeding to permanent implant.

SNM efficacy evidence for urinary indications: Studies and meta-analyses report SNM provides significant reductions in micturition frequency, urgency, and UUI episodes compared to baseline; pooled test success ~66% and permanent success ~82-84% in nLUTD meta-analysespooled estimates

See cited systematic reviews and RCTs for duration and subgroup variability.

Comparative findings vs BTX and PTNS: Network and randomized trials indicate SNM and botulinum toxin are among efficacious options for refractory UUI/OAB; SNM shows durable reductions in incontinence episodes though BTX has higher rates of urinary retention and UTI

OAB / UUI — covered with criteria

Coverage considerations derived from guideline statements and evidence summaries in these chunks.

OAB / UUI (non-neurogenic): Offer SNM for patients with OAB/UUI refractory to conservative and medical therapy after a documented trial phase or PNE; SNM is an established option with long‑lasting effects but notable adverse event and revision riskrefractory after behavioral and pharmacologic therapy; successful trial-phase/PNE

AUA/SUFU, EAU and ICS recommend offering SNM; life‑long surveillance recommended for implanted patients.

Fecal incontinence / LARS — covered with criteria

Evidence supports SNM for fecal incontinence and low anterior resection syndrome (LARS) after failure of conservative measures.

Fecal incontinence / LARS: Consider SNM for individuals with moderate or severe fecal incontinence or LARS who have failed a trial of conservative measures (including biofeedback) and have no contraindications; high PNE response rates and clinical success after permanent implantation are reportedfailure of conservative therapy; consideration of PNE prior to permanent implant

ACG and AGA recommend SNM for FI; systematic reviews report improvements but also infection, pain, mechanical issues, and notable revision/explant rates.

Constipation / STC — not routinely covered

Evidence for SNM in constipation/STC is inconsistent and insufficient; some RCTs show no benefit versus sham, while recent trials show promising short-term results.

Constipation / STC: Evidence is insufficient to support routine use of SNM for constipation; consider only in research settings or specialized centers when alternatives are exhausted, with informed consent regarding uncertain long‑term benefit and notable complication ratesrefractory idiopathic STC despite standard therapies

Some RCTs show no benefit compared with sham while recent trials show short‑term improvements; long‑term effectiveness and safety remain uncertain.

Neurogenic urinary/fecal dysfunction — conditional coverage

Evidence is limited but suggests selected individuals with neurogenic bladder or neurologic disease may benefit from SNM; careful selection required.

Neurogenic bladder / neurogenic FI: Consider SNM in carefully selected patients with neurogenic bladder or bowel dysfunction refractory to conservative treatments, who are at low risk of upper tract deterioration, and who understand device limitations; use a trial‑phase/PNE to assess candidacyrefractory to conservative measures; successful trial-phase/PNE; low risk of upper tract deterioration

Systematic reviews show improvements in multiple parameters but study quality varies; specialist evaluation and counseling required.

Chronic pelvic pain / IC/BPS — conditional/limited

SNM has shown symptom improvement for some CPP and IC/BPS patients, but evidence is limited and variable by etiology.

Chronic pelvic pain / IC/BPS: SNM may be considered for refractory interstitial cystitis/bladder pain syndrome or chronic pelvic pain after thorough assessment and failure of conservative therapies; evidence is limited and variable by etiologyrefractory after conservative care; individualized decision‑making; trial‑phase advisable

Systematic reviews report symptom and QoL improvements in some series but call for randomized prospective trials for definitive recommendations.

Eligibility and trial-to-implant criteria

Covered when ALL of the following guideline-based conditions are met (per cited societies):

Primary indication: Patient has refractory overactive bladder/urge urinary incontinence, non-obstructive urinary retention, or fecal incontinence that has failed conservative and medical therapies (e.g., anticholinergics); consider after botulinum toxin if failed or not acceptable

Sources: EAU, ICS, NICE; patient age ≥18 years per policy

Specialist assessment: Patient selection and treatment should occur in specialist units or after multidisciplinary team review as recommended

Document MDT or specialist evaluation per guidance

Informed consent and counseling: Preoperative counseling documented including risks (infection, pain, need for reprogramming/revision/removal), long‑term commitment, and need for surveillance/battery replacement

NICE and ICS guidance recommend documenting discussion of long‑term implications

Contraindications

Not covered / Contraindications (absolute and relative) — SNM is not appropriate when ANY of the following absolute contraindications are present:

Absolute contraindications: Insufficient clinical response to a therapeutic trial; inability to operate the device without supportive caregivers; pregnancy

Listed as absolute contraindications by consensus guidance

Relative contraindications: Severe or rapidly progressive neurologic disease; established complete spinal cord injury; anticipated need for MRI of body parts below the head; abnormal sacral anatomy

Consider risks versus benefits; may preclude SNM

Use of sacral nerve stimulation (SNS/SNM) for the treatment of Constipation and Chronic Pelvic Pain is considered unproven and not medically necessary. Multiple systematic reviews and randomized trials report inconsistent results for refractory constipation, including cross-over trials showing no difference between active and sham stimulation and heterogeneous safety and reoperation rates; likewise, evidence for chronic pelvic pain is limited to small trials and series without sufficient high-quality data to establish efficacy. Therefore permanent SNS implantation for these indications is not supported as a standard therapy outside of research settings.

There is insufficient evidence to support sacral nerve stimulation (SNS) as a definitive standard of care for chronic pelvic pain (CPP). Systematic reviews include few randomized trials and many small case series; authors conclude neuromodulation for CPP is a developing field and additional high-quality, randomized studies are required before SNS can be recommended as routine therapy.

Routine use of sacral neuromodulation (SNM) for chronic functional constipation (refractory idiopathic slow transit constipation) is not supported due to inconsistent and conflicting evidence. Several systematic reviews and randomized studies report no significant benefit versus sham in some trials, and heterogeneity across studies limits confidence in effectiveness; SNM for refractory constipation should be considered investigational or limited to clinical trials and specialized centers.

SNM for chronic constipation is not FDA‑approved in the United States for this indication and the body of evidence is limited. ASCRS guidance notes SNM may be effective in selected patients with successful PNE testing when conservative measures fail, but recommends further evidence to define appropriate patient selection, test success criteria, and long-term benefit before routine adoption.

This policy is provided for informational purposes and does not constitute medical advice. Coverage determinations are governed by applicable federal, state, or contractual benefit plan terms; when conflicts exist those governing terms shall control. Providers should verify specific benefit and authorization requirements prior to requesting services.

Sacral nerve stimulation (SNS/SNM) for Constipation and Chronic Pelvic Pain is explicitly identified in this policy as unproven and not medically necessary because current evidence does not demonstrate sufficient safety and efficacy to support routine therapeutic use for these conditions.

Evidence supporting rechargeable or newer SNM systems for non‑standard indications is limited by small sample sizes, lack of parallel controls, and risk of bias in key studies. These limitations reduce confidence in comparative effectiveness claims and may lead payers to consider the evidence insufficient without documented trial‑phase response and prior therapeutic failure.

Permanent implantation of SNM for refractory constipation is not supported by randomized evidence demonstrating sustained benefit over sham stimulation. Key randomized trials and systematic reviews show either no significant difference or lack of long‑term follow-up to establish durable effectiveness, so routine permanent implantation for constipation is not endorsed outside investigational contexts.

The presence of relative contraindications—such as severe or rapidly progressive neurologic disease, established complete spinal cord injury, anticipated need for MRI of body parts below the head, or abnormal sacral anatomy—may render sacral nerve stimulation inappropriate. Clinical determination requires specialist judgment and thorough documentation of risks versus benefits prior to proceeding.

Coding — Procedure, Supply, and Diagnosis Codes

Procedure CPT/Therapy CodesCPT

0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed.
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator.
0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed.
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

HCPCS Supply/Device CodesHCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Diagnosis ICD-10 Codes (Urinary and Fecal Indications)ICD-10

N32.81	Overactive bladder.
N32.9	Bladder disorder, unspecified.
N39.3	Stress incontinence (female) (male).
N39.41	Urge incontinence.
N39.42	Incontinence without sensory awareness.
N39.46	Mixed incontinence.
N39.490	Overflow incontinence.
N39.498	Other specified urinary incontinence.
R30.0	Dysuria.
R30.1	Vesical tenesmus.

1–10 of 35

1/4

Added ICD-10 Diagnosis Codes (Urinary Indications)ICD-10

R35.81	Listed as added ICD-10 diagnosis code (urinary indication)
R39.191	Listed as added ICD-10 diagnosis code (urinary indication)
R39.192	Listed as added ICD-10 diagnosis code (urinary indication)

Screening trial responder threshold — ≥ 50% improvement in reported symptoms

Screening trial responder threshold≥ 50% improvement in reported symptoms during screening trial

Trial-defined alternative success≥50% improvement in UI or urinary frequency or return to <8 voids/day (used in some trials)

Permanent implantation requirementPermanent implantation requires ≥50% improvement on the screening trial

Minimum bladder capacity — ≥ 100 mL

Minimum bladder capacity≥ 100 mL

Context

Provider Actions — Authorization, Documentation, and Patient Selection

Prior Authorization

Verify benefit plan and authorization requirements

Prior authorization may be implied for procedures/devices listed by code; verify the member's benefit plan and any state, federal, or contractual authorization requirements before proceeding. This policy is informational — the governing benefit plan controls coverage and preauthorization rules.

Verify federal, state, and contractual benefit plan coverage and authorization requirements prior to scheduling
Listing of a code in this policy does not guarantee coverage or payment

Documentation Required

Trial required before permanent implant

A trial (test) stimulation or percutaneous nerve evaluation (PNE) is required and must be documented prior to permanent implantation. Permanent implantation is considered medically necessary only when the individual demonstrates a successful trial with ≥50% improvement in reported symptoms or return to normal voiding parameters as defined in clinical trials.

Background and Evidence Summary

Sacral nerve stimulation (SNS/SNM) is an implantable neurostimulation therapy used primarily for overactive bladder, urge incontinence, nonobstructive urinary retention, and fecal incontinence. A short screening trial (commonly 3–7 days for bladder indications) identifies responders—typically defined as achieving ≥50% symptom improvement—who may be considered for permanent implantation. SNS is being explored for other indications but evidence for those uses remains limited.

Definitions

Chronic Pelvic Pain — definition (key-value)

DefinitionChronic Pelvic Pain (CPP) is persistent or recurrent episodic pelvic pain associated with lower urinary tract, sexual, bowel, or gynecological dysfunction without proven infection or other obvious pathology

ScopeMay be associated with urinary, sexual, bowel or gynecological symptoms

Evidence statementPolicy notes limited and variable evidence for SNM in CPP; considered unproven for routine use

Chronic Urinary Retention — PVR threshold and persistence definition

PVR thresholdPostvoid residual (PVR) ≥ 300 mL

DurationPersists for ≥ 6 months

Provider Resources and Notes

Note

Revision History

2026-05-01policy_revisionLatest

Policy revised: replaced 'Sacral Nerve Stimulation' with 'Sacral Nerve Stimulation (neurostimulation)'; added medical records documentation requirements and added Fowler's Syndrome definition; added ICD-10 codes R35.81, R39.191, R39.192; updated supporting information (Clinical Evidence, FDA, References); archived previous version CS358ID.A.

1997-09-01regulatory_note

FDA granted Premarket Approval (PMA) for InterStim to treat overactive bladder (P970004); subsequent approvals for urinary retention and InterStim Micro noted (historical supporting information updated).

OpenPayer

Sacral Nerve Stimulation for Urinary and Fecal Indications (for Idaho Only)

Coverage Criteria — Sacral Nerve Stimulation

Coding — Procedure, Supply, and Diagnosis Codes

Provider Actions — Authorization, Documentation, and Patient Selection

Background and Evidence Summary

Definitions

Provider Resources and Notes

Revision History